Nanobiotix(US:NBTX) Globenewswire·2025-09-30 20:15Core Insights - NANOBIOTIX reported significant operational progress and financial results for the first half of 2025, highlighting a strong increase in revenue and a reduction in net loss compared to the previous year [1][6]. Operational Highlights - The clinical development program for JNJ-1900 (NBTXR3) is gaining momentum, with the first patient dosed in the CONVERGE study for Stage 3 unresectable non-small cell lung cancer [4]. - Regulatory harmonization has been achieved, reclassifying JNJ-1900 (NBTXR3) from a medical device to a drug in major European countries [4]. - The company is actively pursuing non-dilutive financing to extend its cash runway beyond mid-2026 [4][11]. Financial Results - Revenue and other income for the six months ended June 30, 2025, increased to €26.6 million from €9.3 million in the same period of 2024, largely due to a positive non-cash revenue impact of €21.2 million from a J&J amendment [2]. - R&D expenses decreased to €14.5 million from €22.0 million year-over-year, primarily due to reduced clinical development activities following the transfer of the NANORAY-312 study sponsorship to J&J [3]. - SG&A expenses remained stable at €11.3 million compared to €10.8 million in the previous year [5]. Net Loss and Cash Position - The net loss attributable to common shareholders for the first half of 2025 was €5.4 million, a significant reduction from €21.9 million in the same period of 2024 [6]. - Cash and cash equivalents as of June 30, 2025, were €28.8 million, down from €49.7 million at the end of 2024 [6][9]. Financial Guidance - The company anticipates that its cash and cash equivalents will fund operations into mid-2026, consistent with prior guidance [7].